Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life

Basit Öğe Kaydı
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authoridBaysal, Mehmet/0000-0001-7681-4623
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorUmit, Elif G.
dc.contributor.authorKirkizlar, Hakki Onur
dc.contributor.authorOzdover, Ali Caner
dc.contributor.authorDemir, Ahmet Muzaffer
dc.date.accessioned2024-06-12T11:03:10Z
dc.date.available2024-06-12T11:03:10Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractHereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominantly inherited disorder characterized by bleeding episodes. These episodes tend to happen spontaneously and reduce the quality of life. Patients are often unresponsive to local measures. With the pathophysiological role of angiogenesis in HHT, antiangiogenic drugs including thalidomide are used to control bleeding episodes. In our study, we evaluated 6 patients with HHT, calculating their Epistaxis Severity Score (ESS) and performing a quality of life assessment with the 36-Item Short Form Health Survey Questionnaire (SF-36), and we studied the alterations of these evaluations with thalidomide treatment. Three patients were male and three were female. Mean age was 60.50 years. No side effects were observed during the treatment period. Improvements of certain SF-36 dimensions including physical functioning, physical component summary, and mental component summary and of the ESS were observed after treatment. Thalidomide may be effective to control bleeding episodes with a reasonable tolerance profile in patients with HHT.en_US
dc.identifier.doi10.4274/tjh.galenos.2018.2018.0190
dc.identifier.endpage47en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue1en_US
dc.identifier.pmid29880465en_US
dc.identifier.scopus2-s2.0-85061161128en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage43en_US
dc.identifier.trdizinid353568en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2018.2018.0190
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/353568
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21560
dc.identifier.volume36en_US
dc.identifier.wosWOS:000458334600007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHereditary Hemorrhagic Telangiectasiaen_US
dc.subjectThalidomideen_US
dc.subjectEpistaxisen_US
dc.subjectQuality Of Lifeen_US
dc.titleThalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Lifeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu